about
Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express PreM and E glycoproteins of Japanese encephalitis virusRodent-borne diseases and their risks for public healthIdentification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans.Protection of mice from fatal measles encephalitis by vaccination with vaccinia virus recombinants encoding either the hemagglutinin or the fusion proteinRecombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infectionA poxvirus-derived vector that directs high levels of expression of cloned genes in mammalian cells.Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral ProteinsCytotoxic T cells from human immunodeficiency virus type 2-infected patients frequently cross-react with different human immunodeficiency virus type 1 clades.Highly attenuated vaccinia virus mutants for the generation of safe recombinant virusesTransfer of the inducible lac repressor/operator system from Escherichia coli to a vaccinia virus expression vectorVaccination against tumor cells expressing breast cancer epithelial tumor antigen.Vaccinia virus vectors: new strategies for producing recombinant vaccines.Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys.Expression of Mycobacterium tuberculosis and Mycobacterium leprae proteins by vaccinia virus.Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections in vivo.Role of cell signaling in poxvirus-mediated foreign gene expression in mammalian cellsImmunogenicity and protection studies with recombinant mycobacteria and vaccinia vectors coexpressing the 18-kilodalton protein of Mycobacterium lepraeEnhancement of CD8(+) T-cell memory by removal of a vaccinia virus nuclear factor-κB inhibitor.Concepts and strategies for human gene therapy.Progress in DNA-based heterologous prime-boost immunization strategies for malaria.Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins.Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 proteinDetection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLAPoxviral vectors for cancer immunotherapyFBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens.Syntaxin 4, VAMP2, and/or VAMP3/cellubrevin are functional target membrane and vesicle SNAP receptors for insulin-stimulated GLUT4 translocation in adipocytesVesicular stomatitis virus Indiana glycoprotein as a T-cell-dependent and -independent antigen.Insertional inactivation of the vaccinia virus 32-kilodalton gene is associated with attenuation in mice and reduction of viral gene expression in polarized epithelial cells.Vaccinia virus preferentially enters polarized epithelial cells through the basolateral surface.The 32-kilodalton envelope protein of vaccinia virus synthesized in Escherichia coli binds with specificity to cell surfaces.Insertion of the human immunodeficiency virus CD4 receptor into the envelope of vesicular stomatitis virus particles.Immunological principles and emerging strategies of vaccination for the elderly.Plaque size phenotype as a selectable marker to generate vaccinia virus recombinantsThe immunogenicity of VP7, a rotavirus antigen resident in the endoplasmic reticulum, is enhanced by cell surface expression.Increased expression in vivo and in vitro of foreign genes directed by A-type inclusion body hybrid promoters in recombinant vaccinia viruses.The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals.Identification of the thymidine kinase gene of feline herpesvirus: use of degenerate oligonucleotides in the polymerase chain reaction to isolate herpesvirus gene homologs.A single point mutation of Ala-25 to Asp in the 14,000-Mr envelope protein of vaccinia virus induces a size change that leads to the small plaque size phenotype of the virus.Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors.
P2860
Q27486585-C1508BFB-DEA1-4784-9181-3C20C9BCE7A2Q28249580-3FFE68DB-FC93-486A-B4E1-9EBFD8C287CCQ33271767-1325ABA0-35FC-47EB-9F85-FC58F342A2BCQ33554501-AB5C269A-FB1F-4FDC-956C-40316B31707FQ33604990-5C2DA05E-5A18-4D3B-87BF-25D1FD4083BEQ33684465-E845C39C-92FF-435C-84DA-87A876C13295Q33770634-9B2ECEA9-E69E-4A9E-861B-4E7142000F96Q33782497-3D7D6875-EE9C-4890-B402-C4B500732E36Q33838030-965DF18D-2042-4636-B190-31BF8852769AQ33849466-FFDE9CEB-A685-4A7A-ACA8-CBE6BD96D4CAQ33920696-901E6771-6821-4881-B466-CB08E2097764Q34211635-36675B44-7B5A-49B4-94F1-2B40C6FEB2E9Q34227778-701D2B4E-EB81-47EB-A3F1-3102A818BC08Q35109573-7A96824E-17AE-4535-99B6-1A984DCB3FE1Q35263067-A846F3D5-3E4F-406E-9D85-086508E49E6FQ35292450-33A88AF0-E286-4FC2-A37C-7FFB7E4E2FA6Q35499788-8C064C7E-8E56-4B7B-ABEC-4AAE521638FFQ35512353-5AFF8BFC-EF34-4A74-8DC4-F9C359DCABFEQ35816188-28E1EB35-82BF-4E65-B4B8-8438D0F435CFQ35826388-3FF0369C-0BCA-45FD-8BA1-45D92B579267Q35887822-79576049-4506-4859-8911-94F87506EAE2Q36137980-46B85F1F-9BCA-48B4-AF78-BD458AFEECE4Q36238343-06A47F8E-A7C9-48D1-A013-424E473B1E0BQ36350388-BBDB447B-1E7C-4B11-A981-6FADB099F42DQ36355924-602B40AA-A5F2-47C4-9FC0-409495A141D1Q36567925-C2B5B5B8-57CE-4507-A279-08E03865E990Q36634104-04B26D0B-48F7-4BFF-BCB7-170555F97564Q36655962-825E49CD-F732-4ED9-B91D-88FC5993F09DQ36688197-6E749EB5-8AB8-4118-A2DC-9456A4C71BBBQ36688206-015DCAEE-DB62-40A8-AE07-FA34918B49D3Q36692234-4348FA00-C61A-4476-9DAE-C5653FE33B2CQ36728309-5925EBA6-5BB7-4040-B40A-B08396D191C2Q36781179-2C30E4AF-C3B9-4650-92FB-69BEB8549F87Q36783893-97E13C75-5CA5-49BA-9432-C010F9D72133Q36798603-1CC10879-1A7A-474C-9318-9A469A2E7BC9Q36798882-F3B08DF2-4EEF-4A25-8DAC-85D239B1BFBAQ36829677-5D057160-52CF-4C51-91A8-ED39FC944EAEQ36831398-D6AFAA30-8EAA-42CF-AEDA-39A91A48D71AQ36866619-989AB229-198F-4729-A524-04501FDEBA1AQ36868255-EB1C81A2-ED00-4CF7-978F-0A08DEC41DF8
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Vaccinia virus expression vectors.
@en
type
label
Vaccinia virus expression vectors.
@en
prefLabel
Vaccinia virus expression vectors.
@en
P1476
Vaccinia virus expression vectors.
@en
P2093
P304
P356
10.1146/ANNUREV.IY.05.040187.001513
P577
1987-01-01T00:00:00Z